BLPH Bellerophon Therapeutics Inc.

1.07
-0.03  -3%
Previous Close 1.10
Open 1.10
Price To book -53.50
Market Cap 37995950
Shares 35,510,234
Volume 311,653
Short Ratio 13.11
Av. Daily Volume 342,093

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 171088092
  2. 8-K - Current report 171085914
  3. 8-K - Current report 171067473
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171010146
  5. 8-K - Current report 171010118

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated May 2016. Data presented at American Thoracic Society (ATS) Conference, May 21 2017. Phase 2b planned for 2018.
INOpulse delivery device
Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF)
Phase 3 commenced enrollment June 2016. Interim analysis and top-line data due 2018.
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 2 trial met primary endpoint - noted September 5, 2017.
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)

SEC Filings

  1. 8-K/A [Amend] - Current report 171088092
  2. 8-K - Current report 171085914
  3. 8-K - Current report 171067473
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171010146
  5. 8-K - Current report 171010118
  6. 8-K - Current report 171002998
  7. S-8 - Securities to be offered to employees in employee benefit plans 17975493
  8. 8-K - Current report 17860938
  9. D - Notice of Exempt Offering of Securities 17856920
  10. SC 13G - Statement of acquisition of beneficial ownership by individuals 17853908